JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 ...
JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 ...
Oceanography ranked No. 5 in the United States and No. 7 in the world. Atmospheric science placed No. 8 nationally and No. 11 ...
Newspoint on MSN
Bihar class 12 Hindi exam 2026: Key details and preparation tips
Overview of the Class 12 Hindi Exam The Bihar School Examination Board (BSEB) has scheduled the Class 12 Hindi examination ...
GlobalData on MSN
Zhejiang Longsheng assumes full control of DyStar
Zhejiang Longsheng Group has acquired full ownership of DyStar, a speciality chemical company, following the resolution of a ...
The PIMCO Dynamic Income Strategy Fund offers an 8.64% yield and trades at a -12% discount to NAV, rare among PIMCO CEFs. PDX ...
Newspoint on MSN
Bihar Board 12th Hindi model paper 2026: Understand the exam pattern and question distribution
The Bihar School Examination Board (BSEB) will conduct the Class 12 Hindi exam on 9th February 2026. To help students prepare effectively, the board has released the model paper, which explains the ...
Brookfield Asset Management offers strong dividend yield and growth, with low risk and exposure to private markets. See why I ...
SCM Champs Positions Enterprises for Early Adoption of SAP Logistics Management Ahead of 2026 Launch WILMINGTON, DE, UNITED STATES, January 5, 2026 /EINPresswire.com/ — SCM Champs today announced its ...
Any repurchases will be funded from the Company’s existing cash balances, future operating cash flows, or other legally available funds. Repurchases will be conducted in accordance with the Company’s ...
CI Global Asset Management ("CI GAM") announces the confirmed annual reinvested capital gains distributions (the "Reinvested Distributions") for the 2025 tax year for the CI ETFs listed below.
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results